Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

Inclusion criteria

• Age between 40-85 years old.
• A diagnosis of IPF that fulfills American Thoracic Society (ATS) / European Respiratory Society (ERS) 2018 consensus criteria within 5 years.
• Ability and willingness to give informed consent and adhere to study requirements.
• Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) >0.70.
• High or mixed affinity binder for TSPO ligands based on genotyping for single-nucleotide polymorphism (SNP)rs6971.

Exclusion criteria

• Acute exacerbation of IPF within <30 days
• Diagnosis of Diabetes Mellitus (Type 1 or Type 2).
• Diagnoses of current infection by clinical or microbial assessments.
• Treatment for >14 days within the preceding month with >20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant.
• Subjects with prior radiation therapy to the thorax.
• Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration.
• Severe cardiovascular disease, defined as any of the following within the preceding 12 weeks: acute myocardial infarction or unstable angina, a coronary revascularization procedure, or stroke.
• Subjects with known liver disease.
• Diagnosis of any active cancer with the exception of basal cell carcinoma of skin.
• Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.
• Active cigarette smoking or vaping